DRUG
Eloralintide
Administered SC
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Status
Recruiting
Phase
Phase 3
Enrollment
1,980
Locations
162
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.
Interventions
Treatment arms and agents.
DRUG
Placebo
Administered SC
Timeline
From registration to results.
First posted
Jan 7, 2026
Study start
Feb 6, 2026
Primary completion
Mar 2028
Study completion
Jul 2030
Results posted
Not reported
Registry updated
Jul 17, 2026
Outcomes
What the study measures.
Primary outcomes
Percent Change from Baseline in Body Weight
Time frame · Baseline, Week 64
Secondary outcomes
Percent Change from Baseline in Total Body Fat Mass
Time frame · Baseline, Week 64
Change from Baseline in Waist Circumference
Time frame · Baseline, Week 64
Percent Change from Baseline in Triglycerides
Time frame · Baseline, Week 64
Change from Baseline in Systolic Blood Pressure (SBP)
Time frame · Baseline, Week 64
Time to Onset of Type 2 Diabetes (T2D)
Time frame · Baseline to Week 168 and Week 191
Time to Onset of Type 2 Diabetes (T2D) in Participants with Prediabetes at Randomization
Change from Baseline in Body Mass Index (BMI)
Time frame · Baseline, Week 64
Change from Baseline in Hemoglobin A1c (HbA1c)
Time frame · Baseline, Week 64
Percent Change from Baseline in Fasting Insulin
Time frame · Baseline, Week 64
Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)
Time frame · Baseline, Week 64
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
Time frame · Baseline, Week 64
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Have Body Mass Index (BMI) at screening of the following: * 30 kilogram per square meter (kg/m2) OR * 27 kg/m2 with at least one of the following weight-related health conditions at screening: * high blood pressure * dyslipidemia * obstructive sleep apnea, or * heart disease * Have a stable body weight (\<5% body weight change) for 90 days prior to screening. * Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight Exclusion Criteria: * Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening) * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) * Have type 1 diabetes or type 2 diabetes * Have had within 90 days prior to screening: * heart attack * stroke * coronary artery revascularization * unstable angina, or * hospitalization due to congestive heart failure * Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure * Have taken medications or alternative remedies intended for weight loss within 90 days of screening
Study locations
162 registered sites.
Argentina · Australia · Belgium · Brazil · Canada · China · Germany · India · Japan · Poland · Puerto Rico · South Korea · Taiwan · United Kingdom · United States. Showing up to 24 locations stored in the fast local snapshot.
MFA Clinical Research
Tuscaloosa, Alabama, United States
Headlands Research - Scottsdale
Scottsdale, Arizona, United States
Neighborhood Healthcare Institute of Health
Escondido, California, United States
Ark Clinical Research - Fountain Valley
Fountain Valley, California, United States
Desert Oasis Healthcare Medical Group
Palm Springs, California, United States
Peninsula Research Associates
Rolling Hills Estates, California, United States
Care Access - Sacramento
Sacramento, California, United States
Southern California Clinical Research
Santa Ana, California, United States
University Clinical Investigators, Inc.
Tustin, California, United States
Chase Medical Research, LLC
Waterbury, Connecticut, United States
JEM Research Institute
Atlantis, Florida, United States
BioMed Research & Medical Center
Miami, Florida, United States
Adult Medicine of Lake County, Inc.
Mt. Dora, Florida, United States
American Research Centers of Florida
Pembroke Pines, Florida, United States
AHF Pensacola
Pensacola, Florida, United States
IMA Clinical Research St. Petersburg
St. Petersburg, Florida, United States
Teak Research Consults - Dunwoody
Dunwoody, Georgia, United States
Teak Research Consults
Lawrenceville, Georgia, United States
Clinical Research Atlanta
Stockbridge, Georgia, United States
East-West Medical Research Institute
Honolulu, Hawaii, United States
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, United States
Cotton O'Neil Clinical Research Center
Topeka, Kansas, United States
Care Access - Lake Charles (Bayou Pines)
Lake Charles, Louisiana, United States
MedStar Good Samaritan Hospital
Baltimore, Maryland, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Eloralintide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 1
Not yet recruiting
56
2026-07
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
1,481
2026-07
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly · Obesity · Overweight
Phase 2
Active, not recruiting
367
2026-07
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
200
2026-07
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly · Overweight · Obesity
Phase 3
Recruiting
1,035
2026-07
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Eli Lilly · Osteoarthritis · Overweight or Obesity
Phase 3
Recruiting
900
2026-07
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly · Sleep Apnea, Obstructive · Obesity
Phase 3
Recruiting
800
2026-07
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Eli Lilly · Overweight · Obesity
Phase 3
Recruiting
900
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.